Acute myeloid leukaemia
RecruitingStudy on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy
Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy
- Disease:Acute myeloid leukaemia
- Substances:AzacitidineRevumenib+1
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Azacitidine
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting







